Welcome to M2Gen

Bringing personalized cancer medicines to market for improved patient health...

M2Gen®, H. Lee Moffitt Cancer Center & Research Institute’s wholly owned, for-profit subsidiary, advances personalized medicine by using high quality tissue, clinical data and molecular technology to advance personalized cancer treatments.

M2Gen’s goal is to accelerate science that will:

• Identify an individual’s susceptibility to disease
• Predict how a given patient will respond to a particular drug, and
• Match patients to best-in-class therapeutics.

To achieve this, M2Gen, along with Moffitt Cancer Center and the 17 hospitals in our Consortium Network , have created the world’s largest cancer-focused biorepository linked to longitudinal clinical and derived molecular data. With more than 80,000 patients across the United States currently enrolled in our long-term observational research study, M2Gen has collected more than 35,000 tumor specimens. Over 350 new patients enroll in the study each week – vastly expanding M2Gen’s knowledge base of clinical, pathologic, demographic, and biomarker data.

Our people are our greatest asset, and to that end, we are committed to becoming “The Employer of Choice” in Florida’s biotech and healthcare industry. With the support of the State of Florida, Hillsborough County, and the City of Tampa, M2Gen currently employs more than 150 people and is dedicated to growth.

Building on M2Gen’s successful partnership with Merck & Co., M2Gen is also interested in developing relationships with new investors and potential pharmaceutical and biotechnology partners who share our vision for transforming cancer treatment and improving patient outcomes.